Zai Lab Unveils Breakthrough ADC ZL-1310 for Solid Tumor Treatment

CAR-T Digest - August 2020

13 Mar 2024: Zai Lab Unveils Breakthrough ADC ZL-1310 for Solid Tumor Treatment

Zai Lab to present preclinical study findings on ZL-1310 at ELCC 2024
ZL-1310 is a novel ADC targeting Delta-like ligand 3 (DLL3) for small cell lung cancer (SCLC) treatment
High affinity for DLL3 and releases its payload intracellularly and in the tumor microenvironment
Preclinical data indicate strong binding to DLL3, leading to tumor cell internalization, cell cycle arrest, and apoptosis induction
ZL-1310 effectively suppresses tumor growth in CDX and PDX xenograft models
Discovered with MediLink Therapeutics’ TMALIN platform, Zai Lab initiated a Phase 1 study for relapsed and refractory SCLC